Clinical trials: sponsored by Royal Marsden NHS Foundation Trust
Prostate Cancer, BRCA Mutation
The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer
The IMPACT study is an international targeted prostate screening study of men at increased prostate cancer risk due to the presence of known pathogenic mutations in BRCA1 and BRCA2 genes and Mis-Match Repair genes (MLH1, MSH6…
- Conditions
- Prostate Cancer, BRCA Mutation, Mismatch Repair Gene Mutation, Genetic Predisposition to Disease
- Trial name
- NCT00261456
- Testing
- PSA test, Prostate Biopsy
- Where
- United Kingdom
- Volunteers
- 3,500 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer
Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
The SAFE-DE study investigates whether circulating tumour DNA (ctDNA) testing can guide adjuvant treatment decisions in patients with stage I breast cancer, identifying those who may be able to avoid chemotherapy after surgery.
- Trial name
- Safe-De (NCT05058183)
- Testing
- ctDNA
- Where
- 13 sites in United Kingdom
- Volunteers
- 800 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Tumor Burden, Neuroendocrine (NE) Tumors
Multicenter Study for External Validation of the TB-NET Score
This is a retrospective, observational, multicenter study aiming to externally validate the TB-NET Score in an independent cohort of patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors…
- Trial name
- TB-NET (NCT07903532)
- Where
- 11 sites in United States, Brazil and 7 more
- Volunteers
- 400 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Colorectal Cancer, Gastro-oesophageal Adenocarcinoma
Cohort Study to eLucidAte Causes, Behaviour and Outcomes of gastRo Intestinal Tract Cancers in the Young
This study aims to better understand how gastrointestinal (digestive system) cancers develop and how they respond to treatment in young adults, in order to improve ways to prevent, diagnose, and manage these cancers in this age…
- Conditions
- Colorectal Cancer, Gastro-oesophageal Adenocarcinoma, Hepato-Biliary Carcinoma in Situ Nos
- Trial name
- CLARITY (NCT07903571)
- Testing
- Research blood samples
- Volunteers
- 200 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Endometrial Carcinoma (EC)
A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility
The goal of this clinical trial is to assess the safety and feasibility of using a new form of radiotherapy technology, known as CT online-adaptive radiotherapy, to reduce the number of treatment sessions required in…
- Trial name
- SHORTEN (NCT07675733)
- Testing
- Hypofractionated CT online adaptive radiotherapy (CT-OART) with dose of 30 Gray in 5 fractions, over one and a half weeks
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
The BALANCE Study: BlAck and Mixed Men's Lived Experience With Prostate cANCEr-Diversity in Prostate Cancer PROMS Study
The BALANCE study is a prospective Patient Reported Outcomes Measures (PROMs) study developed to look at the quality of life (QoL) of patients diagnosed with prostate cancer (PCa) in communities underrepresented in research…
- Trial name
- BALANCE (NCT07529418)
- Testing
- Patient Reported Outcome Measurements (PROMs)
- Where
- Netherlands
- Volunteers
- 800 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Solid Tumours, Multiple Myeloma
Phase I Trial of VS-6766 Alone and in Combination With Everolimus
This study is a multi-centre, investigator-initiated, Phase I clinical trial evaluating different dosing schedules of VS-6766, given either alone or in combination with everolimus, in patients with advanced solid tumours or…
- Conditions
- Solid Tumours, Multiple Myeloma, Lung Cancer, Ovarian Cancer
- Trial name
- RAF/MEK (NCT02407509)
- Testing
- VS-6766, Everolimus
- Where
- 3 sites in United Kingdom
- Volunteers
- 104 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer, Prostate Biopsy
The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment
Prostate cancer is now the most common cancer in men in the Western world. In the United Kingdom (UK), there were over 52,000 new cases diagnosed in 2016-2018 and a lifetime risk of 1 in 8.
- Conditions
- Prostate Cancer, Prostate Biopsy, Genetic Counselling, Genetic Markers
- Trial name
- PROFILE (NCT02543905)
- Testing
- Prostate MRI and Biopsy
- Where
- United Kingdom
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom
HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS)
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma (CCS).
- Trial name
- NCT06942442
- Testing
- Physician's Choice, Tebentafusp
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 47 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Prostate Cancer
Prostate Cancer in UK Prisons: A Retrospective Data Analysis
Prostate cancer is the most common cancer affecting men in the United Kingdom (UK) and is the most common cancer in UK prisons. Early diagnosis is vital because treatment is more effective when the disease is detected at an early…
- Trial name
- PRISON-UK (NCT07870707)
- Where
- United Kingdom
- Volunteers
- 9,007 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Cancer
Digital Body Mindset Intervention for Young Cancer Survivors
The aim of this study is to assess whether a digital body mindset intervention - EMBody - can instil adaptive mindsets and improve health and wellbeing in young cancer survivors aged 16-25.
- Trial name
- EMBody (NCT06702371)
- Testing
- Mindset Intervention
- Where
- United Kingdom
- Volunteers
- 105 people
- Sponsor
- King's College London
Prostate Cancer
Identifying the Best Follow up Approach for People Who Have Had Treatment to Cure Newly Diagnosed Prostate Cancer
Over 20,000 patients a year in the UK get surgery or radiotherapy to cure their prostate cancer. These men then undergo regular check-ups to manage potential side effects and see if cancer recurs so it can be treated quickly.
- Trial name
- FOLLOW-UP (NCT07264088)
- Testing
- Hospital based follow up, Primary care based follow up, Planned shared care follow up
- Where
- United Kingdom
- Volunteers
- 100,000 people
- Sponsor
- Imperial College London
Oesophageal Cancer, Oesophageal Adenocarcinoma
Evaluation of Seismocardiography(SCG) for Assessing Fitness and Predicting Outcomes in Oesophageal Cancer Surgery
Oesophageal cancer is a common cause of cancer death worldwide. Curative treatment involves chemotherapy and surgery but has significant risks.
- Conditions
- Oesophageal Cancer, Oesophageal Adenocarcinoma, Prehabilitation, Oesophagectomy
- Trial name
- SEISMIC (NCT07159711)
- Testing
- Seismofit
- Where
- 4 sites in United Kingdom
- Volunteers
- 164 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Melanoma (Skin Cancer), Non Small Cell Lung Cancer
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
The trial will test if the combination of bexmarilimab and nivolumab can help patients whose cancers have stopped responding to immunotherapy treatment. It will focus on two cancers: non-small cell lung cancer and melanoma.
- Conditions
- Melanoma (Skin Cancer), Non Small Cell Lung Cancer, Solid Tumor in Advanced Stage
- Trial name
- BLAZE (NCT07718243)
- Testing
- Bexmarilimab 1mg/kg and nivolumab 1mg/kg, Bexmarilimab 3mg/kg and nivolumab 1mg/kg, Recommended Phase II Dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 62 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- ASpiRE (NCT07002320)
- Testing
- SX-682, Apalutamide
- Where
- 4 sites in Switzerland, United Kingdom
- Volunteers
- 78 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ)…
- Conditions
- Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer
- Trial name
- ZODIAC (NCT06250036)
- Testing
- Single agent zimberelimab, Combination zimberelimab + domvanalimab
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Triple Negative Breast Cancer, Locally Advanced Breast Cancer
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
This clinical study is aiming to determine the safest doses and schedule for the combination of two drugs named palbociclib and avelumab.
- Conditions
- Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer
- Trial name
- PAveMenT (NCT04360941)
- Testing
- Palbociclib, Avelumab
- Where
- 9 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma)
5G-EMERALD: Amivantamab in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of amivantamab and to determine the preliminary antitumour activity of amivantamab administered at the recommended Phase 2 dose (RP2D).
- Conditions
- Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Glioblastoma Multiforme (GBM)
- Trial name
- 5G-EMERALD (NCT06632236)
- Testing
- Amivantamab
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostate Cancer
UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies
The UKGPCS was set up to find genetic alterations which occur in patients who have prostate cancer. A man's risk of developing prostate cancer increases if he has a first-degree relative (father or brother) who was diagnosed with…
- Trial name
- UKGPCS (NCT01737242)
- Where
- United Kingdom
- Volunteers
- 23,826 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom